Array Biopharma (ARRY) Misses Q4 EPS by 1c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures steady with focus on Mideast talks, US-China summit
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018
August 14, 2018 8:00 AM EDTBOULDER, Colo., Aug. 14, 2018 /PRNewswire/ --Â Array BioPharma Inc. (Nasdaq: ARRY) today reported results for its fourth quarter and full year of fiscal 2018 and provided an update on the progress of its key commercial products and clinical development programs.
"We were thrilled to launch BRAFTOVI + MEKTOVI® for patients with BRAF-mutant melanoma in the U.S. after receiving FDA approval for the combination in June. Since then, we have seen a very positive reception from melanoma healthcare providers. With the announcement of a median overall survival of 33.6 months from the Phase 3... More
